Cardio-oncology: an update on cardiotoxicity of cancer-related treatment
CG Lenneman, DB Sawyer - Circulation research, 2016 - Am Heart Assoc
Through the success of basic and disease-specific research, cancer survivors are one of the
largest growing subsets of individuals accessing the healthcare system. Interestingly …
largest growing subsets of individuals accessing the healthcare system. Interestingly …
Cardio-Oncology Education and Training: JACC Council Perspectives
JA Alvarez-Cardona, J Ray, J Carver, V Zaha… - Journal of the American …, 2020 - jacc.org
The innovative development of cancer therapies has led to an unprecedented improvement
in survival outcomes and a wide array of treatment-related toxicities, including those that are …
in survival outcomes and a wide array of treatment-related toxicities, including those that are …
iPSC-MSCs with high intrinsic MIRO1 and sensitivity to TNF-α yield efficacious mitochondrial transfer to rescue anthracycline-induced cardiomyopathy
Mesenchymal stem cells (MSCs) can donate mitochondria and rescue anthracycline-
induced cardiomyocyte (CM) damage, although the underlying mechanisms remain elusive …
induced cardiomyocyte (CM) damage, although the underlying mechanisms remain elusive …
[HTML][HTML] Согласованное мнение российских экспертов по профилактике, диагностике и лечению сердечно-сосудистой токсичности противоопухолевой …
ЮА Васюк, ГЕ Гендлин, ЕИ Емелина… - Российский …, 2021 - cyberleninka.ru
АВ—атриовентрикулярный (ая) АГ—артериальная гипертензия АД—артериальное
давление АТ—артериальный тромбоз АТО—атеротромботические осложнения АТФ …
давление АТ—артериальный тромбоз АТО—атеротромботические осложнения АТФ …
Mitochondrial sirtuin-3 (SIRT3) prevents doxorubicin-induced dilated cardiomyopathy by modulating protein acetylation and oxidative stress
MM Tomczyk, KG Cheung, B Xiang… - Circulation: Heart …, 2022 - Am Heart Assoc
Background: High doses of doxorubicin put cancer patients at risk for developing dilated
cardiomyopathy. Previously, we showed that doxorubicin treatment decreases SIRT3 (sirtuin …
cardiomyopathy. Previously, we showed that doxorubicin treatment decreases SIRT3 (sirtuin …
Potent paracrine effects of human induced pluripotent stem cell-derived mesenchymal stem cells attenuate doxorubicin-induced cardiomyopathy
Transplantation of bone marrow mesenchymal stem cells (BM-MSCs) can protect
cardiomyocytes against anthracycline-induced cardiomyopathy (AIC) through paracrine …
cardiomyocytes against anthracycline-induced cardiomyopathy (AIC) through paracrine …
[HTML][HTML] Doxorubicin downregulates autophagy to promote apoptosis-induced dilated cardiomyopathy via regulating the AMPK/mTOR pathway
S Zhang, X Wei, H Zhang, Y Wu, J Jing… - Biomedicine & …, 2023 - Elsevier
The broad-spectrum antineoplastic drug doxorubicin (DOX) has one of the most serious
chronic side effects on the heart, dilated cardiomyopathy, but the precise molecular …
chronic side effects on the heart, dilated cardiomyopathy, but the precise molecular …
Resveratrol protects against doxorubicin‐induced cardiotoxicity in aged hearts through the SIRT1‐USP7 axis
Key points Doxorubicin induced functional deteriorations and elevations of USP7‐related
apoptotic/catabolic signalling in the senescent heart Resveratrol protects against …
apoptotic/catabolic signalling in the senescent heart Resveratrol protects against …
Allogeneic mesenchymal cell therapy in anthracycline-induced cardiomyopathy heart failure patients: the CCTRN SENECA trial
Background Anthracycline-induced cardiomyopathy (AIC) may be irreversible with a poor
prognosis, disproportionately affecting women and young adults. Administration of …
prognosis, disproportionately affecting women and young adults. Administration of …
Comparison of long‐term outcome in anthracycline‐related versus idiopathic dilated cardiomyopathy: a single centre experience
Aims Cardiac dysfunction is a severe complication of anthracycline‐containing anticancer
therapy. The outcome of anthracycline‐induced cardiomyopathy (AICM) compared with …
therapy. The outcome of anthracycline‐induced cardiomyopathy (AICM) compared with …